


# Chemical Science

Volume 11  
Number 14  
14 April 2020  
Pages 3577–3754

rsc.li/chemical-science



ISSN 2041-6539

**EDGE ARTICLE**

Min Li, Liang Hong *et al.*  
Efficient synthesis of cyclic amidine-based fluorophores *via*  
6 $\pi$ -electrocyclic ring closure

Cite this: *Chem. Sci.*, 2020, 11, 3586

All publication charges for this article have been paid for by the Royal Society of Chemistry

Received 11th February 2020  
Accepted 4th March 2020

DOI: 10.1039/d0sc00798f

rsc.li/chemical-science

## Efficient synthesis of cyclic amidine-based fluorophores via $6\pi$ -electrocyclic ring closure†

Guofeng Li,<sup>†</sup> Man Zhao,<sup>‡</sup> Junqiu Xie,<sup>‡</sup> Ying Yao,<sup>a</sup> Lingyun Mou,<sup>b</sup> Xiaowei Zhang,<sup>b</sup> Xiaomin Guo,<sup>b</sup> Wangsheng Sun,<sup>b</sup> Zheng Wang,<sup>c</sup> Jiecheng Xu,<sup>a</sup> Jianzhong Xue,<sup>a</sup> Tao Hu,<sup>a</sup> Ming Zhang,<sup>b</sup> Min Li<sup>\*a</sup> and Liang Hong<sup>id</sup>\*<sup>a</sup>

Novel  $10\pi$ -electron cyclic amidines with excellent fluorescence properties were synthesized by a general and efficient  $6\pi$ -electrocyclic ring closure of ketenimine and imine starting from *N*-sulfonyl triazoles and arylamines. The photophysical properties of cyclic amidine fluorophores have been studied in detail and have shown good properties of a large Stokes shift, pH insensitivity, low cytotoxicity and higher photostability, which have great potential for biological imaging. Furthermore, this novel fluorophore was successfully applied to the localization of the NK-1 receptor in living systems.

### Introduction

Small organic fluorophores have been used widely in biological science and drug discovery due to their easy handling, high sensitivity and minimal disruption to living systems.<sup>1</sup> Although a large variety of fluorescent small molecules have been developed, their core scaffolds are still limited to several types such as prodan, fluorescein, coumarin *etc.*,<sup>2</sup> most of which usually possess a  $\pi$ -conjugated system with an electron-donating and an electron-withdrawing group located at the opposite position of the fluorescent moiety (Fig. 1).<sup>3</sup> On the other hand, the ideal fluorophores for living systems with good photophysical properties including a large Stokes shift, an applicable pH environment, good stability and low biological toxicity are in high demand. Consequently, the development of small organic fluorophores with a new framework and good photophysical properties is an appealing and challenging task.<sup>4</sup>

To develop a new fluorescent framework, we wondered whether it is possible to incorporate an electron-donating and an electron-withdrawing group at the adjacent position of a  $\pi$ -system. Considering the particularity of this structure, we tried

to choose  $\pi$ -system cyclic amidines as the core structure of novel fluorophores, not only due to their potent fluorescence properties,<sup>5</sup> but also due to the electronic specificity of amidines (Fig. 1). However, how to incorporate an amidine into a  $\pi$ -system is a challenge, since the synthesis of such a scaffold is limited and difficult. Moreover, it usually needs a variety of cyclic amidines with structural diversity to study the fluorescence–structure relationship. Thus, it is necessary yet challenging to develop a simple and short synthetic route to access various cyclic amidines.

*N*-Sulfonyl-1,2,3-triazoles have become an important class of intermediates for accessing a wide variety of complex molecular scaffolds.<sup>6</sup> Metal-bound imino carbenes, readily generated from *N*-sulfonyl 1,2,3-triazoles, have found wide application in many useful transformations, including cycloaddition, X–H insertion, alkyl migration, sigmatropic rearrangement and some other carbene induced reactions.<sup>6,7</sup> In addition to imino carbenes, *N*-sulfonyl-1,2,3-triazoles could also form active ketenimine intermediates, which would readily undergo nucleophilic additions at C2.<sup>8</sup> In particular, the ketenimines containing

<sup>a</sup>Guangdong Key Laboratory of Chiral Molecular and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China. E-mail: limin65@mail.sysu.edu.cn; hongliang@sysu.edu.cn

<sup>b</sup>Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China

<sup>c</sup>Guangdong Key Lab of Nano-Micro Material Research, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China

† Electronic supplementary information (ESI) available: Details of the experimental procedure, structural characterization and spectral data of all new compounds and crystallographic data (CIF). CCDC 1942349. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/d0sc00798f

‡ These authors contributed equally to this work.





Fig. 1 Structural characteristics of traditional fluorophores and amidines.





Scheme 1 Related research and this work.

another electrophilic site would undergo double nucleophilic addition with amines to give cyclic amidines (Scheme 1a).<sup>9</sup> Moreover, ketenimines could also in whole or in part participate in some cyclization reactions. For example, in the [1,5]-X sigmatropic shift/6 $\pi$ -electrocyclic ring closure (6 $\pi$ -ERC), the whole ketenimines (C=C=NTs) take part in the reaction to give dihydroisoquinolines (Scheme 1b),<sup>8f,10</sup> while part of the ketenimines (C=C) in the [2 + 2] cycloadditions reacts to give amidines (Scheme 1c).<sup>11</sup> From these studies, we found that cyclic amidines could be constructed by the intramolecular conjunction of a nitrogen atom to the C2 of the ketenimine. Accordingly, we designed the intermediate **A** functionalized with an adjacent imine and ketenimine. The imine bond (C=NAr) was introduced for the formation of 6 $\pi$ -substrates suitable for ERC and might react with part of the ketenimines to give cyclic amidine products (Scheme 1d).

## Results and discussion

With this reaction design in mind, we first investigated the reaction of *N*-sulfonyl triazoles **1a** with phenylamine **2a** as the model reaction in the presence of a catalyst at 120 °C in a sealed tube for 2 h (Table 1). A low yield of 17% was observed in the presence of a CuI catalyst (entry 1). We also examined some other catalysts including Cu(OAc)<sub>2</sub>, CuTc, Rh<sub>2</sub>(OAc)<sub>4</sub>, Rh<sub>2</sub>(Oct)<sub>4</sub> and Pd(OAc)<sub>2</sub>, and they gave yields ranging from 12% to 54% (entries 2–6). Interestingly, when the reaction was conducted in the absence of any catalyst, the reaction could give a significant improvement of the yield to 83% (entry 7). Increasing the reaction time to 4 h could further improve the yield to 91% (entry 8), but further increasing the reaction time to 10 h reduced the yield to 86% (entry 9). After screening several solvents, CHCl<sub>3</sub> was found to be the optimum solvent for this reaction (entries 8–13).


Under optimal conditions, the scopes of the reaction were examined as shown in Scheme 2. We first examined the scope of benzenamines with various substituents at different positions. The reaction proceeded efficiently to afford the corresponding cyclic amidines **3aa–3ar** in good to excellent yields, though

Table 1 Optimization of the reaction conditions<sup>a</sup>

Entry	Cat.	Solvent	<i>t</i> (h)	Yield <sup>b</sup> (%)
1	CuI	CHCl <sub>3</sub>	2	17
2	Cu(OAc) <sub>2</sub>	CHCl <sub>3</sub>	2	26
3	CuTc	CHCl <sub>3</sub>	2	46
4	Rh <sub>2</sub> (OAc) <sub>4</sub>	CHCl <sub>3</sub>	2	23
5	Rh <sub>2</sub> (Oct) <sub>4</sub>	CHCl <sub>3</sub>	2	54
6	Pd(OAc) <sub>2</sub>	CHCl <sub>3</sub>	2	54
7	—	CHCl <sub>3</sub>	2	83
8	—	CHCl <sub>3</sub>	4	91
9	—	CHCl <sub>3</sub>	10	86
10	—	Toluene	4	40
11	—	DCE	4	77
12	—	THF	4	30
13	—	1,4-Dioxane	4	44

<sup>a</sup> Conditions: **1a** (0.10 mmol, 1.0 equiv.), **2a** (0.12 mmol, 1.2 equiv.), the catalyst (0.005 mmol, 5 mol%), and solvent (2.0 mL) in a sealed tube.  
<sup>b</sup> Isolated yield.

higher reactivity was observed with electron-donating groups. Significantly, the benzenamines with functional groups such as azide, hydroxy and carboxyl groups were well tolerated to give **3as–3au**, which could be modified easily for the purpose of bioconjugate chemistry. Some other amines, including naphthyl amine, 2-aminopyridine and phenylhydrazine were also

Scheme 2 Scope of the reaction. Conditions: **1** (0.10 mmol, 1.0 equiv.), **2** (0.12 mmol, 1.2 equiv.) and the solvent (2.0 mL) in a sealed tube for 4 h at 120 °C. <sup>a</sup> 1 mmol scale.




Fig. 2 DFT calculations for the transformation of ketenimine A.

suitable substrates for the reaction, leading to the desired products **3av–3ax** in moderate yields. The structure of **3aw** was determined by X-ray crystallography.<sup>12</sup> The scope of *N*-sulfonyl-1,2,3-triazoles was subsequently investigated. The reaction took place with moderate to excellent yields with substrates bearing different substituents **3ba–3be**.

To further understand the formation of cyclic amidine **3aa**, analysis by DFT calculations was performed. As shown in Fig. 2, starting from ketenimine intermediate **A**, there are two pathways to proceed. By path a, the intermediate **A** could undergo  $6\pi$ -electrocyclic ring closure ( $6\pi$ -ERC) via  $TS_{A-B}$  to give **B (3aa)**; while by path b, the intermediate **A** could undergo the first [1,5]-H shift to form the intermediate **C**, followed by the  $6\pi$ -ERC via  $TS_{C-D}$  to afford the isoquinolone **D**. The energy for the formation of  $TS_{A-B}$  ( $\Delta G = 7.2$  kcal mol<sup>-1</sup>) is lower than that for the  $TS_{C-D}$  ( $\Delta G = 30.2$  kcal mol<sup>-1</sup>). Therefore, the intermediate **A** favors path a to furnish the observed product **3aa**.

With a series of  $10\pi$ -electron cyclic amidines in hand, we measured their photophysical properties including absorptions, emissions, extinction coefficients, Stokes shifts and quantum yields. As shown in Table 2, the maximum absorption wavelengths ( $\lambda_{max}$ ) varied from 424 to 443 nm with moderate extinction coefficients ( $2110$ – $4364$  M<sup>-1</sup> cm<sup>-1</sup>), while the maximum emission wavelengths ( $\lambda_{em}$ ) varied from 525 to 552 nm with quantum yields from 1% to 23%. In addition, cyclic amidines **3as–3au** with functional groups exhibited similar photophysical properties, which could be conveniently modified for further fluorophore tagging.

Table 2 Spectral properties of fluorophores

Compound	$\lambda_{max}^a$ (nm)	$\lambda_{em}^a$ (nm)	$\epsilon^b$ (M <sup>-1</sup> cm <sup>-1</sup> )	Stokes shift (nm)	$\Phi^c$ (%)
Coumarin <sup>1,3d</sup>	386	448	36 700	62	70
Fluorescein <sup>3bd</sup>	490	512	93 000	22	95
<b>3aa</b>	433	535	2110	102	17
<b>3ab</b>	432	527	3066	95	23
<b>3ac</b>	434	542	3613	108	14
<b>3ad</b>	434	538	3790	104	13
<b>3ae</b>	436	543	3588	107	11
<b>3af</b>	437	545	3440	108	12
<b>3ag</b>	434	538	3558	104	16
<b>3ah</b>	434	541	3430	107	17
<b>3ai</b>	434	535	3312	101	19
<b>3aj</b>	435	536	2770	101	15
<b>3ak</b>	435	540	3209	105	14
<b>3al</b>	436	542	3786	106	14
<b>3am</b>	435	543	3418	108	12
<b>3an</b>	433	536	4364	103	19
<b>3ao</b>	434	537	3874	103	18
<b>3ap</b>	432	525	2804	93	22
<b>3aq</b>	434	530	3917	96	18
<b>3ar</b>	433	539	3578	106	14
<b>3as</b>	435	535	2915	100	18
<b>3at</b>	434	538	3250	104	18
<b>3au</b>	434	536	2935	102	17
<b>3av</b>	434	532	3170	98	18
<b>3aw</b>	437	552	3099	115	1
<b>3ax</b>	425	528	3865	103	16
<b>3ba</b>	440	542	2285	102	09
<b>3bb</b>	443	550	3771	107	09
<b>3bc</b>	443	547	2796	104	10
<b>3bd</b>	427	536	3853	109	17
<b>3be</b>	424	535	2458	111	12

<sup>a</sup> Measured in CH<sub>3</sub>CN at 200  $\mu$ M. <sup>b</sup> Molar extinction coefficient. <sup>c</sup> Absolute fluorescence quantum yield determined with an integrating sphere system. <sup>d</sup> The structures of coumarin and fluorescein are shown in Fig. 1.





A good fluorophore for living systems has good properties including a remarkable Stokes shift, an applicable pH environment, high photostability and low biological toxicity. Keeping this in mind, we further examined these photophysical properties (Fig. 3). Based on the absorption and emission wavelengths in Table 2, all cyclic amidines exhibited remarkable Stokes shifts of  $\sim 100$  nm, which could minimize self-absorption and provide better fluorescence imaging. We next studied the effect of pH on cyclic amidine **3aa**. The results showed that the pH value of the environment ranging from 2.8–11.4 had no effect on the emissive properties (Fig. 3c). In addition, amidine **3aa** showed excellent resistance to photobleaching with only 3.4% fluorescence lost after one hour at the wavelength of maximum excitation (Fig. 3d).<sup>14</sup> Subsequently, the impact of different solvent environments was investigated. As shown in Fig. 3e, **3aa** worked well in aqueous environments, indicating that it could be used as a polarity probe. In addition, the emission intensity could be maintained in aqueous solution without loss after 24 h (see the ESI<sup>†</sup>). Moreover, cytotoxicity was another important factor for its application in living systems. We evaluated the cytotoxicity of **3aa** by using CCK-8 assays for HeLa cells, and it exhibited no significant cytotoxicity at concentrations of up to 100  $\mu\text{M}$  (Fig. 3f). These results demonstrated that the novel amidine fluorophore has good properties of a large Stokes shift, pH insensitivity, low cytotoxicity and good photostability, which has great potential for biological imaging.

Ligand-based probes<sup>15</sup> have received extensive attention and have extensive applications due to their high selectivity and

affinity in the visualization of receptor–ligand interactions and drug evaluation. In order to evaluate the potential of cyclic amidines for cell imaging, we synthesized a fluorescent probe **4** by conjugating cyclic amidine **3au** with the hemokinin-1 (HK-1) peptide (TGKASQFFGLM-NH<sub>2</sub>), which was highly selective to the NK-1 receptor (Fig. 4a).<sup>16</sup> The neurokinin-1 (NK-1) receptor, as a member of the G-protein-coupled receptor (GPCR) family, is located at the cell membrane. If a fluorescent ligand binds to the NK-1 receptor, it would give fluorescence signals at the cell membrane. To test whether fluorescent probe **4** could bind to the NK-1 receptor, WT 22RV1 and NK-1-overexpressing 22RV1 cells were treated with **4** respectively. As Fig. 4 shows, green fluorescence could only be observed in the cell membrane of NK-1-overexpressing 22RV1, not in the cell membrane of WT 22RV1. Furthermore, the fluorescence could be blocked with




Fig. 3 (a) The photophysical properties were examined using **3aa** as a representative. (b) Normalized absorbance (abs) and emission (em) spectra of **3aa** in CH<sub>3</sub>CN. (c) **3aa** was prepared as a 1 mM stock solution in DMSO and then diluted to a concentration of 10  $\mu\text{M}$  with phosphate buffers of different pH values prepared in advance. Emission spectra were measured at 433 nm excitation. (d) Test of the photostability of **3aa** ( $\lambda_{\text{ex}} = 433$  nm) in CH<sub>3</sub>CN at 100.0  $\mu\text{M}$ . (e) Emission spectra of **3aa** in various solvents at 20  $\mu\text{M}$ . (f) Cell viability (%) was measured by using CCK-8 assays, treated in the presence of 6.25–200  $\mu\text{M}$  of **3aa** using WT HeLa cells for 24 h at 37 °C.





Fig. 4 (a) Synthesis and structure of fluorescent ligand **4** (**3au**-N-hemokinin-1). (b) WT 22RV1 cells and fluorescence images of 22RV1 cells treated with **4** (1  $\mu\text{M}$ ) at 37 °C for 30 min. (c) NK-1-overexpressing 22RV1 cells and fluorescence images of 22RV1 cells treated with **4** (1  $\mu\text{M}$ ) at 37 °C for 30 min. (d) NK-1-overexpressing 22RV1 cells treated with the NK1R inhibitor aprepitant (1  $\mu\text{M}$ ) at 37 °C for 30 min and then incubated with fluorescent ligand **4** (1  $\mu\text{M}$ ) for 30 min at 37 °C. Excitation wavelength 488 nm and emission wavelength 520 nm.



aprepitant, a selective NK-1 receptor antagonist, indicating that the fluorescent ligand **4** was specifically bound to the NK-1 receptor. These preliminary results demonstrated that amidine fluorophores could be used as potential bioprobes.

## Conclusions

In summary, we have developed a general and efficient  $6\pi$ -electrocyclic ring closure of ketenimine and imine starting from *N*-sulfonyl triazoles and arylamines. The method provides expeditious access to a variety of  $10\pi$ -electron cyclic amidines in moderate to excellent yields. Through a fluorescence–structure relationship study, we found that cyclic amidine fluorophores have the advantages of large Stokes shifts, pH insensitivity, low cytotoxicity and higher photostability. Furthermore, they can be used efficiently in developing new fluorescent probes for imaging in living systems.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

We would like to dedicate this to Professor Albert S. C. Chan on the occasion of his 70th birthday. We are grateful for financial support from the NSFC (21871296 and 21907111), the Guangdong Natural Science Funds for Distinguished Young Scholars (2017A030306017) and the Fundamental Research Funds for the Central Universities (19ykpy128).

## Notes and references

- (a) J. Chan, S. C. Dodani and C. J. Chang, *Nat. Chem.*, 2012, **4**, 973–984; (b) Q. Shao and B. Xing, *Chem. Soc. Rev.*, 2010, **39**, 2835–2846; (c) W. Sun, S. Guo, C. Hu, J. Fan and X. Peng, *Chem. Rev.*, 2016, **116**, 7768–7817; (d) M. Vendrell, D. Zhai, J. C. Er and Y. T. Chang, *Chem. Rev.*, 2012, **112**, 4391–4420; (e) J. Zhang, R. E. Campbell, A. Y. Ting and R. Y. Tsien, *Nat. Rev. Mol. Cell Biol.*, 2002, **3**, 906–918; (f) H. Zhu, J. Fan, J. Du and X. Peng, *Acc. Chem. Res.*, 2016, **49**, 2115–2126; (g) I. Johnson and M. T. Z. Spence, *The Molecular Probes Handbook, A Guide to Fluorescent Probes and Labeling Technologies*, Molecular Probes, Eugene, OR, 11th edn, 2010.
- (a) S. M. Barbon, V. N. Staroverov and J. B. Gilroy, *J. Org. Chem.*, 2015, **80**, 5226–5235; (b) E. Benedetti, L. S. Kocsis and K. M. Brummond, *J. Am. Chem. Soc.*, 2012, **134**, 12418–12421; (c) A. N. Butkevich, M. V. Sednev, H. Shojaei, V. N. Belov and S. W. Hell, *Org. Lett.*, 2018, **20**, 1261–1264; (d) R. Greiner, D. S. Ziegler, D. Cibu, A. C. Jakowetz, F. Auras, T. Bein and P. Knochel, *Org. Lett.*, 2017, **19**, 6384–6387; (e) V. Jamsheena, R. K. Mishra, K. S. Veena, S. Sini, P. Jayamurthy and R. S. Lankalapalli, *ACS Omega*, 2018, **3**, 856–862; (f) E. Kim, M. Koh, B. J. Lim and S. B. Park, *J. Am. Chem. Soc.*, 2011, **133**, 6642–6649.
- (a) L. D. Lavis and R. T. Raines, *ACS Chem. Biol.*, 2008, **3**, 142–155; (b) A. P. Demchenko, *Advanced Fluorescence Reporters in Chemistry and Biology I*, Springer-Verlag: Berlin, Heidelberg, 2010.
- (a) M. Arribat, E. Remond, S. Clement, A. V. Lee and F. Cavelier, *J. Am. Chem. Soc.*, 2018, **140**, 1028–1034; (b) O. N. Burchak, L. Mugheri, M. Ostuni, J. J. Lacapere and M. Y. Balakirev, *J. Am. Chem. Soc.*, 2011, **133**, 10058–10061; (c) Y. Cheng, G. Li, Y. Liu, Y. Shi, G. Gao, D. Wu, J. Lan and J. You, *J. Am. Chem. Soc.*, 2016, **138**, 4730–4738; (d) Y. Lian, R. G. Bergman, L. D. Lavis and J. A. Ellman, *J. Am. Chem. Soc.*, 2013, **135**, 7122–7125; (e) D. B. Zhao, J. Y. Hu, N. J. Wu, X. L. Huang, X. R. Qin, J. B. Lan and J. S. You, *Org. Lett.*, 2011, **13**, 6516–6519.
- (a) A. R. Longstreet, R. R. Chandler, T. Banerjee, L. Zane Miller, K. Hanson and D. Tyler McQuade, *Photochem. Photobiol. Sci.*, 2017, **16**, 455–458; (b) A. R. Longstreet, M. Jo, R. R. Chandler, K. Hanson, N. Zhan, J. J. Hrudka, H. Mattoussi, M. Shatruk and D. T. McQuade, *J. Am. Chem. Soc.*, 2014, **136**, 15493–15496.
- (a) H. M. Davies and J. S. Alford, *Chem. Soc. Rev.*, 2014, **43**, 5151–5162; (b) Y. Jiang, R. Sun, X. Y. Tang and M. Shi, *Chem.–Eur. J.*, 2016, **22**, 17910–17924; (c) Y. Li, H. Yang and H. Zhai, *Chem.–Eur. J.*, 2018, **24**, 12757–12766.
- Selected examples: (a) J. S. Alford and H. M. Davies, *J. Am. Chem. Soc.*, 2014, **136**, 10266–10269; (b) K. Chen, Z. Z. Zhu, Y. S. Zhang, X. Y. Tang and M. Shi, *Angew. Chem., Int. Ed.*, 2014, **53**, 6645–6649; (c) S. Chuprakov, B. T. Worrell, N. Selander, R. K. Sit and V. V. Fokin, *J. Am. Chem. Soc.*, 2014, **136**, 195–202; (d) J. He, Y. Shi, W. Cheng, Z. Man, D. Yang and C. Y. Li, *Angew. Chem., Int. Ed.*, 2016, **55**, 4557–4561; (e) S. W. Kwok, L. Zhang, N. P. Grimster and V. V. Fokin, *Angew. Chem., Int. Ed.*, 2014, **53**, 3452–3456; (f) V. N. Lindsay, H. M. Viart and R. Sarpong, *J. Am. Chem. Soc.*, 2015, **137**, 8368–8371; (g) S. Y. Liu, W. F. Yao, Y. Liu, Q. H. Wei, J. H. Chen, X. Wu, F. Xia and W. H. Hu, *Sci. Adv.*, 2017, **3**, e1602467; (h) P. Mi, R. Kiran Kumar, P. Liao and X. Bi, *Org. Lett.*, 2016, **18**, 4998–5001; (i) T. Miura, T. Tanaka, T. Biyajima, A. Yada and M. Murakami, *Angew. Chem., Int. Ed.*, 2013, **52**, 3883–3886; (j) E. E. Schultz, V. N. Lindsay and R. Sarpong, *Angew. Chem., Int. Ed.*, 2014, **53**, 9904–9908; (k) Z.-F. Xu, H. Dai, L. Shan and C.-Y. Li, *Org. Lett.*, 2018, **20**, 1054–1057; (l) J. M. Yang, C. Z. Zhu, X. Y. Tang and M. Shi, *Angew. Chem., Int. Ed.*, 2014, **53**, 5142–5146; (m) Y. Yang, M. B. Zhou, X. H. Ouyang, R. Pi, R. J. Song and J. H. Li, *Angew. Chem., Int. Ed.*, 2015, **54**, 6595–6599; (n) Y. Yu, L. Zhu, Y. Liao, Z. Mao and X. Huang, *Adv. Synth. Catal.*, 2016, **358**, 1059–1064; (o) H. Yuan, J. Gong and Z. Yang, *Chem. Commun.*, 2017, **53**, 9089–9092; (p) M. Zibinsky and V. V. Fokin, *Angew. Chem., Int. Ed.*, 2013, **52**, 1507–1510.
- For reviews: (a) I. Bae, H. Han and S. Chang, *J. Am. Chem. Soc.*, 2005, **127**, 2038–2039; (b) S. H. Cho and S. Chang, *Angew. Chem., Int. Ed.*, 2007, **46**, 1897–1900; (c) S. H. Cho and S. Chang, *Angew. Chem., Int. Ed.*, 2008, **47**, 2836–2839; (d) S. H. Cho, E. J. Yoo, L. Bae and S. Chang, *J. Am. Chem. Soc.*, 2005, **127**, 16046–16047; (e) R. H. Dodd and K. Cariou, *Chem.–Eur. J.*, 2018, **24**, 2297–2304; (f) Y. Jiang, R. Sun, Q. Wang, X. Y. Tang and M. Shi, *Chem. Commun.*, 2015, **51**,



- 16968–16971; (g) S. H. Kim, S. H. Park, J. H. Choi and S. Chang, *Chem.-Asian J.*, 2011, **6**, 2618–2634; (h) H. D. Xu, Z. H. Jia, K. Xu, M. Han, S. N. Jiang, J. Cao, J. C. Wang and M. H. Shen, *Angew. Chem., Int. Ed.*, 2014, **53**, 9284–9288; (i) Y. Zhang, K. A. DeKorver, A. G. Lohse, Y. S. Zhang, J. Huang and R. P. Hsung, *Org. Lett.*, 2009, **11**, 899–902.
- 9 (a) S. Chang, M. Lee, D. Y. Jung, E. J. Yoo, S. H. Cho and S. K. Han, *J. Am. Chem. Soc.*, 2006, **128**, 12366–12367; (b) Z. Chen, C. Ye, L. Gao and J. Wu, *Chem. Commun.*, 2011, **47**, 5623–5625; (c) Y. Huang, W. Yi, Q. Sun, L. Zhang and F. Yi, *RSC Adv.*, 2018, **8**, 74–79.
- 10 L. Sun, Y. Zhu, P. Lu and Y. Wang, *Org. Lett.*, 2013, **15**, 5894–5897.
- 11 (a) W. Lu, W. Song, D. Hong, P. Lu and Y. Wang, *Adv. Synth. Catal.*, 2009, **351**, 1768–1772; (b) E. Romero, C. Minard, M. Benchekroun, S. Ventre, P. Retailleau, R. H. Dodd and K. Cariou, *Chem.-Eur. J.*, 2017, **23**, 12991–12994; (c) M. Whiting and V. V. Fokin, *Angew. Chem., Int. Ed.*, 2006, **45**, 3157–3161; (d) Y. Xing, H. Zhao, Q. Shang, J. Wang, P. Lu and Y. Wang, *Org. Lett.*, 2013, **15**, 2668–2671.
- 12 CCDC 1942349.†
- 13 W.-C. Sun, K. R. Gee and R. P. Haugland, *Bioorg. Med. Chem. Lett.*, 1998, **8**, 3107–3110.
- 14 The photobleaching of fluorescein is about 17% after 33 min, see: W.-C. Sun, K. R. Gee, D. H. Klaubert and R. P. Haugland, *J. Org. Chem.*, 1997, **62**, 6469–6475.
- 15 (a) Z. Ma, L. Du and M. Li, *J. Med. Chem.*, 2014, **57**, 8187–8203; (b) H. Shi, R. T. Kwok, J. Liu, B. Xing, B. Z. Tang and B. Liu, *J. Am. Chem. Soc.*, 2012, **134**, 17972–17981; (c) C. Zhang, S. Jin, K. Yang, X. Xue, Z. Li, Y. Jiang, W. Q. Chen, L. Dai, G. Zou and X. J. Liang, *ACS Appl. Mater. Interfaces*, 2014, **6**, 8971–8975.
- 16 (a) F. Bellucci, F. Carini, C. Catalani, P. Cucchi, A. Lecci, S. Meini, R. Patacchini, L. Quartara, R. Ricci, M. Tramontana, S. Giuliani and C. A. Maggi, *Br. J. Pharmacol.*, 2002, **135**, 266–274; (b) J. Li, Q. Zeng, Y. Zhang, X. Li, H. Hu, X. Miao, W. Yang, W. Zhang, X. Song, L. Mou and R. Wang, *Eur. J. Cell Biol.*, 2016, **95**, 368–377; (c) L. Mou, Y. Xing, Z. Kong, Y. Zhou, Z. Chen and R. Wang, *Biochem. Pharmacol.*, 2011, **81**, 661–668; (d) Y. Zhang, L. W. Lu, C. Furlonger, G. E. Wu and C. J. Paige, *Nat. Immunol.*, 2000, **1**, 392–397.

